Search

Displaying results 3571 - 3580 of 10000 in total
  1. Drug

    Sulfinpyrazone

    go.drugbank.com/drugs/DB01138
    Approved

    A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.

    Products: Nu-sulfinpyrazone Tab 200mg, Nu-sulfinpyrazone Tab 100mg
  2. Drug

    Tiocarlide

    go.drugbank.com/drugs/DB13608
    Experimental

    Categories: Drugs for Treatment of Tuberculosis
  3. Drug

    Alphacetylmethadol

    go.drugbank.com/drugs/DB01555
    ExperimentalIllicit

    A narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. [PubChem]

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Midomafetamine

    go.drugbank.com/drugs/DB01454
    IllicitInvestigational

    It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Cefprozil

    go.drugbank.com/drugs/DB01150
    ApprovedInvestigational

    Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.

    Products: Nu-cefprozil, PREFIX 250 MG FILM TABLET, 10 ADET
  6. Drug

    Ropeginterferon alfa-2b

    go.drugbank.com/drugs/DB15119
    ApprovedInvestigational

    [A242010, A242015] Ropeginterferon alfa-2b was approved by the FDA on November 12, 2021, and is currently marketed under the trademark BESREMi by PharmaEssentia Corporation.[L39170]

  7. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

  8. Drug

    Cabazitaxel

    go.drugbank.com/drugs/DB06772
    ApprovedInvestigational

    It was first approved by the FDA on June 17, 2010.[A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376]

    Products: Cabazitaxel EVER Pharma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CABAZITAXEL EVER PHARMA
  9. Drug

    Xenon-133

    go.drugbank.com/drugs/DB09315
    Approved

    Xenon-133 is an inhaled radionuclide used for lung imaging, imaging blood flow in the brain, and to assess pulmonary function.

  10. Drug

    Rifamexil

    go.drugbank.com/drugs/DB20067
    Experimental

    Rifamexil has a monoisotopic molecular weight of 809.36 Da.

    Categories: Heterocyclic Compounds with 4 or More Rings